Andrew Satlin, MD

Somnolence and Sedation with Lumateperone Treatment: A Comparison of Morning and Evening Administration

Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...

Sharon Mates , PhD;

Andrew J. Cutler , MD;

William Rowe , MSN, RN, ACNP, BC;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Jason Huo , PhD;

10/08/2020

Efficacy and Safety of Lumateperone (ITI-007) in the Treatment of Depressive Episodes Associated With Bipolar I and II Disorders

Background: Treatments for bipolar depression are limited. Lumateperone (lumateperone tosylate, ITI-007), a mechanistically novel antipsychotic that simultaneously modulates serotonin, do...

Joseph Calabrese , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Jason Huo , PhD;

Sharon Mates , PhD;

Ian D'Souza , PhD;

Susan Kozauer , MD;

10/08/2020

Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study

Background: Antipsychotic treatment of schizophrenia is often associated with increased rates of metabolic syndrome (MetSy), as defined by criteria for waist circumference, triglycerides,...

Suresh Durgam , MD;

Christoph U. Correll , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

John Edwards , MD, MBA;

Richard Chen , PhD;

10/08/2020

The Efficacy of Lumateperone 42 mg in the Treatment of Schizophrenia: A Pooled Analysis of Randomized Controlled Trials

Introduction: Lumateperone (lumateperone tosylate, ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that simultaneously modu...

Robert Davis , PhD;

Kimberly Vanover , PhD;

Andrew Satlin , MD;

Carol Tamminga , MD;

Sharon Mates , PhD;

Tobie Escher , PhD;

11/22/2019

The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials

Introduction: Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutama...

Andrew Satlin , MD;

Kimberly Vanover , PhD;

Sharon Mates , PhD;

John Kane , MD;

John Edwards , MD, MBA;

Suresh Durgam , MD;

Robert Davis , PhD;

11/22/2019

Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...

Jelena Saillard , MS, MBA;

Christoph U. Correll , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

Kimberly Vanover , PhD;

11/22/2019

Lumateperone in the Treatment of Schizophrenia: Efficacy in Demographic and Clinical Subgroups

Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...

Sharon Mates , PhD;

Kimberly Vanover , PhD;

Ian D'Souza , PhD;

Roger McIntyre , MD, FRCPC;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

11/22/2019

Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study

Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.

Kimberly Vanover , PhD;

Jelena Saillard , MS, MBA;

Steven Glass , MD;

Susan Kazaouer , MD;

Michal Weingart , PhD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

03/01/2019